Clinical Trial Detail

NCT ID NCT02661815
Title A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Recruitment Terminated
Gender female
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

cervical cancer

endometrial cancer

ovarian carcinoma

peritoneal carcinoma

fallopian tube carcinoma

Therapies

Paclitaxel + Ricolinostat

Bevacizumab

Age Groups: adult

No variant requirements are available.